Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 114.76M P/E - EPS this Y 30.70% Ern Qtrly Grth -
Income -108.58M Forward P/E -1.80 EPS next Y 34.00% 50D Avg Chg -11.00%
Sales - PEG 0.02 EPS past 5Y - 200D Avg Chg 36.00%
Dividend N/A Price/Book 0.62 EPS next 5Y -75.30% 52W High Chg -57.00%
Recommedations 1.80 Quick Ratio 12.87 Shares Outstanding 38.25M 52W Low Chg 173.00%
Insider Own 33.29% ROA -32.44% Shares Float 17.13M Beta -
Inst Own 53.33% ROE -56.31% Shares Shorted/Prior 3.07M/4.72M Price 3.00
Gross Margin - Profit Margin - Avg. Volume 3,898,750 Target Price 10.00
Oper. Margin - Earnings Date May 11 Volume 542,494 Change 1.01%
About Pyxis Oncology, Inc.

Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

PYXS Chatroom

User Image ViractaTrader77 Posted - 15 hours ago

$IMGN $PYXS $CTMX $CRBP VIP236 at Vincerx has potential to be a blockbuster like Enhertu. Data coming this year 40x payload as Enhertu.

User Image LabPsycho Posted - 1 day ago

$PYXS I think the Apexigen purchase was for window dressing. As I mentioned months ago, PYXS very early stage with phase 1 end point expected 2025! Thats a long way off and likely a dilution before then. However I think there is a play here later in the year...closer to $2 if / when it gets there. In the meantime, I think a smart move by PYXS would be to purchase another small company early stage like $CNTX trading below cash and targeting a hot molecule. I think it is a great fit with PYXS and could expand their antibody portfolio for cheap. / free just like what they did with APGN.

User Image jiam Posted - 1 day ago

$PYXS ouch

User Image BullMac7 Posted - 1 day ago

$PYXS has anyone read the corporate presentation yet? My personal opinion is to not do yourself a disservice and sell before end of Q3 2023. Never invest more than you’re willing to lose, Rome wasn’t build in a day!

User Image cctranscripts Posted - 1 day ago

Report of proposed sale of securities https://www.conferencecalltranscripts.org/summary/?id=12265585 $PYXS

User Image fla Posted - 1 day ago

$PYXS [15s. delayed] filed form 144 on June 08, 15:57:21 https://s.flashalert.me/783s1

User Image TrooperTrades Posted - 1 day ago

$PYXS what a huge piece of shit this has turned into over the last few months 🤮

User Image User123321 Posted - 1 day ago

$PYXS what’s the near term catalyst here or one by October Opex. OI is small but someone wants those $5 calls. I was trying to buy close some and. M being stepped in front of at $.45. 😀👍🙏

User Image ViractaTrader77 Posted - 1 day ago

$VINC Vincerx must still be in blackout period pending news. Otherwise insiders would be buying IMO. $PYXS $DAWN $LVTX

User Image LabPsycho Posted - 2 days ago

$PYXS @TheDividendDaddy You can read the full document here. Look like Issuing more shares / dilution to current shareholders to pay for the acquisition of APGN https://www.sec.gov/ix?doc=/Archives/edgar/data/1782223/000143774923016930/pyxs20230603_s4.htm

User Image jacckkmm Posted - 2 days ago


User Image EarningsInsider Posted - 2 days ago

Pyxis Oncology, Inc. Files SEC Form S-4 $PYXS https://www.marketbeat.com/stocks/NASDAQ/PYXS/sec-filings/

User Image cctranscripts Posted - 2 days ago

Pyxis Oncology, Inc. just filed its Registration of securities, business com http://www.conferencecalltranscripts.org/include?location=http://www.sec.gov/Archives/edgar/data/1782223/000143774923016930/0001437749-23-016930-index.htm $PYXS

User Image risenhoover Posted - 2 days ago

$PYXS / Pyxis Oncology files form S-4 https://fintel.io/sf/us/pyxs?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

User Image Quantisnow Posted - 2 days ago

$PYXS 📜 SEC Form S-4 filed by Pyxis Oncology Inc. https://quantisnow.com/i/4618106?utm_source=stocktwits 45 seconds delayed.

User Image fla Posted - 2 days ago

$PYXS [15s. delayed] filed form S-4 on June 08, 08:03:22 https://s.flashalert.me/u1Dw4m

User Image TheDividendDaddy Posted - 2 days ago

$PYXS Please explain what PYXS filing Form 144 means for us shareholders?

User Image EarningsInsider Posted - 2 days ago

Pyxis Oncology, Inc. Files SEC Form 144 $PYXS https://www.marketbeat.com/stocks/NASDAQ/PYXS/sec-filings/

User Image cctranscripts Posted - 2 days ago

Report of proposed sale of securities https://www.conferencecalltranscripts.org/summary/?id=12262534 $PYXS

User Image fla Posted - 2 days ago

$PYXS [15s. delayed] filed form 144 on June 07, 19:12:54 https://s.flashalert.me/rusNf

User Image jiam Posted - 2 days ago

$PYXS someone wanted those shares. ..

User Image GreenTsunami Posted - 2 days ago

$PYXS I regret holding this penny stock and not selling earlier a month ago. It's just low volume, no news shit.

User Image AllzGood Posted - 3 days ago

$PYXS Green by EOD

User Image ViractaTrader77 Posted - 3 days ago

$VINC Nobody selling. 100%+ gains coming soon! $CTMX $PYXS $SGEN

User Image euroconversions Posted - 3 days ago

$PYXS https://beststocks.com/citigroup-increases-holdings-in-pyxis-oncology-ai/

User Image KdDoodah Posted - 4 days ago

$PYXS Company to present and host investor meetings at Jefferies Healthcare Conference in NYC on June 7, 2023 BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced dosing of the first subject in the Phase 1 trial of PYX-106. PYX-106 is a fully human immunotherapy antibody candidate that is designed to block the activity of Siglec-15, an immune suppressor expressed across a broad range of tumors. The Company also announced that the second dose level has been initiated in the ongoing Phase 1 trial of PYX-201, a novel antibody-drug conjugate (ADC) product candidate licensed from Pfizer targeting extradomain-B (EDB) of fibronectin, a non-internalizing antigen that is an integral component of the extracellular matrix in tumors.

User Image Dtwood7474 Posted - 4 days ago

$PYXS this still has a few more runs to $4 in it. Going to float between 3-3.50 until major breakout.

User Image Mrmessiah Posted - 4 days ago

$APGN I see what’s going on. It’s just set to algo/follow $PYXS

User Image Dtwood7474 Posted - 5 days ago

$PYXS steady horse right here.

User Image ViractaTrader77 Posted - 1 week ago

$INMB $PYXS I believe Vincerx should be worth more than InmuneBio. And just as much as Pyxis. inmuneBio had heavy insider selling. Hence Vincerx has had heavy insider buying and never any selling plus they are in the smoking hot antibody drug conjugate arena. Plus since Pyxis has the same run way and I value the assets as equal. In conclusion here are 2 bio peers that have market caps of $120 million that I believe VINC should have as well. Especially since VIP236 delivers 40x the payload of the blockbuster Enhertu. Implies $6 stock price or higher! $ADCT $MRSN

Analyst Ratings
Credit Suisse Outperform Mar 23, 23
B of A Securities Neutral Nov 2, 21
Jefferies Buy Nov 2, 21
Credit Suisse Outperform Nov 2, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
PFIZER INC 10% Owner 10% Owner Mar 17 Buy 2.76 1,811,594 4,999,999 5,952,263 03/21/23
Chin Mark Other Other Apr 21 Sell 3.05 1,745,761 5,324,571 04/25/22
Chin Mark Director Director Oct 13 Buy 16 312,500 5,000,000 1,745,761 10/15/21